Merck withdraws EU license application for Movectro

Mavenclad is an oral treatment for relapsing MS and active secondary progressive MS.
Post Reply
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm

Merck withdraws EU license application for Movectro

Post by MSUK » Thu Feb 17, 2011 7:12 am


German drugmaker Merck KGA has withdrawn a European marketing authorisation application for its multiple sclerosis (MS) drug Movectro after it was rejected by EU drug regulators and an appeal was also turned down.

The European Medicines Agency (EMA) said in a statement on Thursday it had been notified by Merck Serono Europe that it was withdrawing its application for 10 milligram tablets of Movectro, which is known generically as cladribine.... Read More - ... ageid/1629

Post Reply
  • Similar Topics
    Last post